Robert E. Landry - 08 Dec 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Finance CFO
Signature: /s/**Robert E. Landry
Issuer symbol: REGN
Transactions as of: 08 Dec 2022
Net transactions value: -$962,523
Form type: 4
Filing time: 12 Dec 2022, 15:34:35 UTC
Previous filing: 02 Dec 2022
Next filing: 20 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$1,145,760	+3,000	+10%	$381.92	31,744	08 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Tax liability	$1,737,669	-2,261	-7.1%	$768.54	29,483	08 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Tax liability	$370,614	-492	-1.7%	$753.28	28,991	09 Dec 2022	Direct
holding	REGN	Common Stock						250	08 Dec 2022	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-3,000	-44%	$0.000000	3,800	08 Dec 2022	Common Stock	3,000	$381.92	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2	The stock option award vests in four equal annual installments, commencing one year after the date of grant.